Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

Annals of Oncology ◽

10.1093/annonc/mds505 ◽

2013 ◽

Vol 24 (2) ◽

pp. 329-336 ◽

Cited By ~ 47

Author(s):

A. Heidenreich ◽

S.K. Rawal ◽

K. Szkarlat ◽

N. Bogdanova ◽

L. Dirix ◽

...

Keyword(s):

Human Monoclonal Antibody ◽

Line Treatment ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Double Blind ◽

Castration Resistant ◽

Multicenter Phase ◽

Phase 2 Study ◽

Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.7515 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 7515-7515 ◽

Cited By ~ 5

Author(s):

Mathias J. Rummel ◽

Michael Koenigsmann ◽

Kai Uwe Chow ◽

Wolfgang Knauf ◽

Christian A. Lerchenmuller ◽

...

Keyword(s):

Marginal Zone ◽

Marginal Zone Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Rituximab Maintenance ◽

Multicenter Phase ◽

Phase 2 Study ◽

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.12.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 228-237 ◽

Author(s):

Noha Rashad ◽

Thoraya Abdelhamid ◽

Samia A. Shouman ◽

Hanan Nassar ◽

Mervat A. Omran ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Gastric Cancer ◽

10.1007/s10120-020-01101-4 ◽

2020 ◽

Vol 24 (1) ◽

pp. 156-167 ◽

Cited By ~ 3

Author(s):

Keun-Wook Lee ◽

◽

Ik-Joo Chung ◽

Min-Hee Ryu ◽

Young Iee Park ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Combination Chemotherapy ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Multicenter Phase ◽

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71159-3 ◽

2015 ◽

Vol 16 (1) ◽

pp. 25-35 ◽

Cited By ~ 947

Author(s):

Richard S Finn ◽

John P Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Oestrogen Receptor ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

First Line ◽

Phase 2 Study ◽

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients

Lung Cancer ◽

10.1016/j.lungcan.2020.06.007 ◽

2020 ◽

Vol 147 ◽

pp. 259-268 ◽

Author(s):

Zhijie Wang ◽

Jun Zhao ◽

Zhiyong Ma ◽

Jiuwei Cui ◽

Yongqian Shu ◽

...

Keyword(s):

Lung Cancer ◽

Chinese Patients ◽

Advanced Lung Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Platinum Based Chemotherapy ◽

Phase 2 Study ◽

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05755-7 ◽

2020 ◽

Vol 183 (2) ◽

pp. 419-428 ◽

Author(s):

Richard S. Finn ◽

Katalin Boer ◽

Igor Bondarenko ◽

Ravindranath Patel ◽

Tamas Pinter ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Cancer Medicine ◽

10.1002/cam4.3091 ◽

2020 ◽

Vol 9 (14) ◽

pp. 4929-4940 ◽

Cited By ~ 2

Author(s):

Masato Takahashi ◽

Norikazu Masuda ◽

Reiki Nishimura ◽

Kenichi Inoue ◽

Shinji Ohno ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1100 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1100-TPS1100 ◽

Author(s):

David Miles ◽

Sung-Bae Kim ◽

V. A. McNally ◽

Brian P. Simmons ◽

Matthew Wongchenko ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Safety And Efficacy ◽

Phase 2 Study ◽